Central regions | Finance, business | Technology & innovation

Diabetic foot treatment raises funding

6 May '19
Russia’s Skolkovo Foundation and Human Stem Cells Institute (HSCI), a private holding company, have announced support for a young Russian company called NextGene, a Skolkovo resident. Of the $492,000 grant funding, an estimated $246,000 is coming from Skolkovo and HSCI is expected to match the amount.

The money will reportedly be used to complete phase 2 of clinical trials for NextGene’s new technology that is expected to help diabetic foot syndrome patients.

The diabetic foot syndrome is one of the most widespread diabetes complications, responsible for 75% of nontraumatic lower extremities amputations globally.

“Independent experts reviewed the project’s grant memo and found no analog of the new substance in the market, as well as a highly competent project team,” said Vladimir Egorov who manages the project at the Skolkovo Foundation’s Biomed Cluster.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Tags: Human Stem Cells Institute (9) / grant (36) / Skolkovo Foundation (30) / diabetic foot (0) / NextGene (0) /

Latest News: Central regions
17 May '19 | Finance, business | Telecoms, media
16 May '19 | Technology & innovation | Finance, business
14 May '19 | Transport, logistics | Finance, business
13 May '19 | Technology & innovation

Feature stories

4 Apr '19
Russian scientists have come up with what they say is...
29 Jan '19
Russian biologists and biophysicists have developed...
2 Nov '18
Drawing upon in-depth interviews, the book channels...
Search (News archive - 21348)
Independent Software Developers Forum
Marchmont News

Latest News

17 May '19
MTS, one of Russia’s main mobile operators, has...
16 May '19
The Skolkovo Foundation and AstraZeneca, an...
15 May '19
Last week Moscow-based HeadHunter Group, a leading...

Most read stories from last week